Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simeprevir plus daclatasvir in chronic hepatitis C with severe renal impairment or hemodialysis
2014-004250-34Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2015
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of simeprevir and daclatasvir in hepatitis C virus infection, sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of participants with sustained virologic response at week 12 after end of treatment. Started Mar 2015; status: terminated.
02
Drugs
simeprevirdaclatasvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2014-004250-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004250-34.